The Monoclonal Antibody Core Facility (MACF) provides the following four high quality services not only at a reasonable cost to investigators but also in a timely manner. 1. The generation of new MAbs / hybridomas to a specific antigen of interest. 2. MAb production (in vitro), purification and modification (including conjugation to fluorphores, biotion and enzymes and the fragmentation of MAbs). 3. Mycoplasma testing of tissue culture samples. 4. In vitro production of recombinant/secreted proteins. Monoclonal antibodies (MAbs) are essential tools used in most if not all fields of biomedical research, in the diagnosis of diseases, and in the treatment of diseases such as infections and cancer. The goal of the MACF is to support the research interests of MSKCC investigators by providing key services related to the production, purification and use of MAbs. Over the last 5 years demand for the MACF services has remained consistently high. From July 2005 through July 2006, 61 investigators from 9 out of 10 programs placed orders with the facility for any combination of the services noted above.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-47
Application #
8375213
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-01-09
Project End
2013-12-31
Budget Start
2012-01-09
Budget End
2012-12-31
Support Year
47
Fiscal Year
2012
Total Cost
$158,120
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Steuer, Conor E; Behera, Madhusmita; Berry, Lynne et al. (2016) Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer 122:766-72
Dominguez-Rosado, Ismael; Moutinho Jr, Vitor; DeMatteo, Ronald P et al. (2016) Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship. J Am Coll Surg 222:961-6
Iasonos, Alexia; O'Quigley, John (2016) Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. Contemp Clin Trials 50:124-34
Ulaner, Gary A; Hyman, David M; Ross, Dara S et al. (2016) Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med 57:1523-1528
Brown, Anna M; Nagala, Sidhartha; McLean, Mary A et al. (2016) Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. Magn Reson Med 75:1708-16
Akkari, Leila; Gocheva, Vasilena; Quick, Marsha L et al. (2016) Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. Genes Dev 30:220-32
Theilen, Till M; Chou, Alexander J; Klimstra, David S et al. (2016) Esophageal Adenocarcinoma and Squamous Cell Carcinoma in Children and Adolescents: Report of 3 Cases and Comprehensive Literature Review. J Pediatr Surg Case Rep 5:23-29
Robinson, June K; Halpern, Allan C (2016) Cost-effective Melanoma Screening. JAMA Dermatol 152:19-21
Calzavara-Pinton, Pier Giacomo; Rossi, Maria Teresa; Zanca, Arianna et al. (2016) Oral Polypodium leucomotos increases the anti-inflammatory and melanogenic responses of the skin to different modalities of sun exposures: a pilot study. Photodermatol Photoimmunol Photomed 32:22-7
Ripley, R Taylor; Suzuki, Kei; Tan, Kay See et al. (2016) Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg 151:969-77, 979.e1-3

Showing the most recent 10 out of 4768 publications